Baseline characteristics | Total N | Remission off medicationa | Not in remissionb | OR (95% CI) | p |
---|---|---|---|---|---|
Gender female, n (%) | 410 | 106 (38.8) | 167 (61.2) | 0.8 (0.5–1.2) | 0.334 |
Age at disease onset, years | 410 | 6.3 (2.5–10.0) | 5.2 (2.5–9.6) | 0.9 (0.9–1.0) | 0.401 |
Time from onset to diagnosis, months | 388 | 1.5 (0.5–2.9) | 1.7 (0.5–3.6) | 1.0 (1.0–1.1) | 0.152 |
Cumulative active joint count | 410 | 2 (1–4) | 4 (2–7) | 1.1 (1.1–1.2) | < 0.001 |
Physician’s global assessment VAS | 227 | 0.8 (0.0–1.3) | 2.0 (1.0–3.8) | 3.5 (1.9–6.2) | < 0.001 |
Polyarticular RF-positive, n (%) | 410 | 1 (25.0) | 3 (75.0) | 2.1 (0.2–20.0) | 0.535 |
Polyarticular RF-negative, n (%) | 410 | 25 (26.9) | 68 (73.1) | 2.2 (1.3–3.6) | 0.003 |
Oligoarticular, n (%) | 410 | 107 (49.1) | 111 (50.9) | 0.5 (0.3–0.7) | < 0.001 |
Psoriatic arthritis, n (%) | 410 | 3 (50.0) | 3 (50.0) | 0.7 (0.1–3.4) | 0.635 |
Enthesitis-related arthritis (ERA), n (%) | 410 | 11 (32.4) | 23 (67.6) | 1.5 (0.7–3.1) | 0.315 |
Undifferentiated arthritis, n (%) | 410 | 19 (34.5) | 36 (65.5) | 1.3 (0.7–2.4) | 0.336 |
ANA-positive, ≤ 6 years, n (%)c | 397 | 22 (31.4) | 48 (68.6) | 1.6 (0.9–2.7) | 0.107 |
Specific joint involvement, n (%) | |||||
 Hip joint | 409 | 18 (32.1) | 38 (67.9) | 1.5 (0.8–2.8) | 0.168 |
 Ankle joint | 409 | 57 (31.0) | 127 (69.0) | 2.1 (1.4–3.1) | < 0.001 |
 Tarsal joint | 409 | 6 (16.7) | 30 (83.3) | 3.8 (1.5–9.2) | 0.004 |
 Subtalar joint | 409 | 14 (26.9) | 38 (73.1) | 2.0 (1.1–3.8) | 0.034 |
 Wrist joint | 409 | 33 (30.6) | 75 (69.4) | 1.8 (1.1–2.9) | 0.014 |
 Finger joint | 409 | 36 (27.7) | 94 (72.3) | 2.3 (1.5–3.6) | < 0.001 |
 Neck | 409 | 9 (26.5) | 25 (73.5) | 2.0 (0.9–4.4) | 0.085 |
 Upper limb joints | 410 | 67 (32.7) | 138 (67.3) | 1.9 (1.3–2.9) | 0.001 |
 Lower limb joints | 410 | 144 (39.0) | 225 (61.0) | 1.8 (0.9–3.5) | 0.073 |
Symmetric involvement, n (%) | |||||
 Hip joints | 409 | 5 (21.7) | 18 (78.3) | 2.6 (0.9–7.1) | 0.067 |
 Ankle joints | 409 | 27 (28.4) | 68 (71.6) | 2.0 (1.2–3.3) | 0.006 |
 Wrist joints | 409 | 22 (34.4) | 42 (65.6) | 1.4 (0.8–2.4) | 0.272 |
 Finger joints | 409 | 13 (22.0) | 46 (78.0) | 2.7 (1.4–5.3) | 0.002 |
Patient-reported outcomes | |||||
 Patient’s/parent’s global assessment VAS | 250 | 0.5 (0.0–2.2) | 1.7 (0.5–3.5) | 2.2 (1.4–3.4) | 0.001 |
 CHAQ score | 257 | 0.1 (0.0–0.6) | 0.5 (0.0–1.1) | 2.0 (1.3–3.0) | 0.002 |
 Pain VAS | 246 | 0.4 (0.0–3.0) | 2.3 (0.5–4.2) | 1.9 (1.3–2.8) | 0.002 |
 Morning stiffness for > 15 min, n (%) | 314 | 25 (22.1) | 88 (77.9) | 3.6 (2.1–6.0) | < 0.001 |
Laboratory tests | |||||
 ESR mm/h | 332 | 11.0 (6.0–18.0) | 17.0 (9.5–34.0) | 1.4 (1.2–1.7) | < 0.001 |
 CRP >10 mg/L, n (%) | 329 | 12 (16.7) | 60 (83.3) | 3.9 (2.0–7.5) | < 0.001 |
 ANA-positive, n (%) | 397 | 37 (33.0) | 75 (67.0) | 1.5 (1.0–2.4) | 0.075 |
 RF-positive, n (%) | 221 | 5 (50.0) | 5 (50.0) | 0.6 (0.2–2.0) | 0.376 |
 HLA-B27 positive, n (%) | 382 | 21 (25.9) | 60 (74.1) | 2.1 (1.2–3.6) | 0.010 |